About Contact Us Careers
Sign In

Neuroblastoma Drugs Market - Top Companies and Manufacturers

  • Report ID: 2769
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Companies Dominating the Neuroblastoma Drugs Landscape

    • CELLECTAR BIOSCIENCES, INC. 
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • APEIRON Biologics AG
    • Pfizer Inc.
    • Eli Lilly and Company
    • AstraZeneca
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • MacroGenics Inc.
    • Marsala Biotech Inc.
    • Johnson & Johnson Services, Inc.
Browse Key Market Insights with Data Illustration:

In the News

  • Teva Pharmaceutical Industries Ltd. in Association with Global HOPE (Hematology Oncology Pediatric Excellence) donated over 566,000 doses of medicine, and helped with the training of over 5,600 healthcare professionals across Africa by providing required care, health services, and medical resources.

  • Eli Lilly and Company started research on genomic testing in cancer in order to find weaknesses in tumor makeup and to design more targeted treatment. Further, Lilly Oncology is working to spread the knowledge about genomic testing in cancer diagnosis and treatment.


Author Credits:  Radhika Pawar


  • Report ID: 2769
  • Published Date: Jun 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of neuroblastoma drugs is evaluated at USD 253.92 Billion.

The neuroblastoma drugs market size was over USD 241.96 Billion in 2023 and is expected to exceed USD 467.68 Billion by 2036, growing at over 5.2% CAGR during the forecast period i.e., between 2024-2036. Increasing the practice of chemotherapy, and a high number of people with early diagnosis test awareness are the major factors driving the market growth.

North America industry is predicted to have the highest growth through 2036, due to rise in technologically enhanced drugs along with the increase in incidences of neuroblastoma.

CELLECTAR BIOSCIENCES, INC., APEIRON Biologics AG, Pfizer Inc., Eli Lilly and Company, AstraZeneca, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, MacroGenics Inc., Marsala Biotech Inc., Johnson & Johnson Services, Inc.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample